This is the authors' abstract. We don't add key points for this paper.
Zolmitriptan is a potent 5-HT(1B/1D) agonist whose targets include the peripheral and central components of the trigeminovascular system. It is generally well-tolerated and has dose-dependent efficacy in the treatment of migraine. The 2.5 mg dose is felt to provide the best balance between efficacy and adverse events. In a direct comparative study, the 2 h headache response rate for zolmitriptan 2.5 mg was statistically superior to sumatriptan 25 and 50 mg, although at 3.3% not clinically significant. Two comparative studies have found no difference in adverse event frequency between zolmitriptan and sumatriptan.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Goads et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: